PPAN-P2RY11

Across TCGA pan-cancer cohorts, PPAN-P2RY11 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPAN-P2RY11 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PPAN-P2RY11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPAN-P2RY11 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, PRAD, and SKCM are the cancer types where PPAN-P2RY11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	All	0.940	0.717	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PPAN-P2RY11–LUAD (OS)

Open the LUAD breakdown →